Novartis‘ Gilenya and interferon beta-1b-based therapies stop multiple sclerosis patients’ cognitive decline, a Phase 4 clinical trial shows.
Gilenya (fingolimod) also reduces patients’ relapses and the number of their brain lesions — areas where a protein coating that protects nerve cells has deteriorated, researchers found.
The study, published in the Journal of Neurology, is titled “Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).”
“Cognitive dysfunction is a common clinical problem in MS and is associated with functional impairment leading to deterioration in patients’ quality of life,” the researchers wrote.
The team wanted to see what effect Gilenya and interferon beta-1b therapies would have on MS patients’ cognitive impairment. Gilenya is an approved therapy for relapsing forms of MS. Interferon beta-1b therapies include Bayer‘s Betaseron.